Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Biogen156 enrolled

Overview

The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric subjects with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and evolution of disability. The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306. The secondary objective of Part 2 is to describe the long-term MS outcomes of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

156

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

dimethyl fumarateDRUG

administered orally

Interferon β-1aDRUG

administered by intramuscular injection

Eligibility

Sex: ALLMin age: 10 YearsMax age: 17 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Must have a body weight of ≥30 kg. * Must have a diagnosis of RRMS (consensus definition for pediatric RRMS \[Krupp 2007\]). * Must be ambulatory with a baseline EDSS score between 0 and 5.5, inclusive. * Must have experienced at least 1 of the following 3 conditions: a) at least 1 relapse within the last 12 months prior to Day 1 with a prior brain MRI demonstrating lesions consistent with MS; b) at least 2 relapses within the last 24 months prior to Day 1, with a prior brain MRI demonstrating lesions consistent with MS; c) evidence of Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to Day 1. * Must be neurologically stable, with no evidence of relapse within 50 days prior to Day 1 and no evidence of corticosteroid treatment within 30 days prior to Day 1. * Subjects of childbearing potential who are sexually active must be willing to practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their final dose of study treatment. Key Exclusion Criteria: * Primary progressive, secondary progressive, or progressive relapsing MS (as defined by \[Lublin and Reingold 1996\]). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses but are distinguished from relapsing-remitting subjects by the lack of clinically stable periods or clinical improvement. * Disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease, lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders. * History of premalignant or malignant disease. Subjects with basal cell carcinoma that has been completely excised prior to screening will remain eligible. * History of severe allergic or anaphylactic reactions, or known drug hypersensitivity to DMF, fumaric acid esters, or interferon beta-1a (IFN Beta-1a). * History of abnormal laboratory results indicative of any significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, renal, and/or any other major disease that would preclude participation in a clinical study. * History of clinically significant cardiovascular, pulmonary, GI, dermatologic, growth, developmental, psychiatric (including depression), neurologic (other than MS), and/or other major disease that would preclude participation in a clinical study. -.History of human immunodeficiency virus. * An MS relapse that has occurred within 50 days prior to Day 1 AND/OR the subject has not stabilized from a previous relapse prior to Day 1. * Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject unsuitable for enrollment. * For the PD/PK subset of subjects: subjects unable to swallow the BG00012 capsule whole. Key Treatment history * Any previous treatment with Fumaderm (fumaric acid esters) or BG00012. * Prior treatment with any of the following: total lymphoid irradiation, cladribine, T-cell or T-cell receptor vaccination, any therapeutic monoclonal antibody, with the exception of rituximab or natalizumab. * Prior treatment with any of the following medications within the 12 months prior to Day 1: mitoxantrone, cyclophosphamide, rituximab. * Prior treatment with any of the following medications or procedures within 6 months prior to Day 1: fingolimod; teriflunomide; natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil; laquinimod; intravenous (IV) immunoglobulin; plasmapheresis or cytapheresis * Treatment with any of the following medications within 30 days prior to Day 1: steroids (IV or oral corticosteroid treatment, including agents that may not act through the corticosteroid pathway \[e.g.low dose naltrexone\]), 4-aminopyridine or related products (except subjects on a stable dose of controlled-release fampridine for 3 months) NOTE: Other protocol-defined inclusion/exclusion criteria may apply

Locations (62)

Outcomes

Primary Outcomes

Proportion of Participants Free of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans

Part 1

Time frame: At week 96

Number of Participants That Experience Adverse Events (AEs) or Serious Adverse Events (SAEs)

Part 2 will be an optional open-label extension phase in subjects who complete Part 1 and who meet the Part 2 entry criteria.

Time frame: Up to 7 years

Number of Participants Who Discontinue Study Treatment due to an AE

Part 2

Time frame: Up to 7 years

Secondary Outcomes

The Number of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans

Part 1

Time frame: At Week 24 and Week 96

Proportion of Participants Free of New/Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans

Part 1

Time frame: At Week 24 and Week 48

Proportion of Participants Free of New MRI Activity as measured by Brain MRI Scans

Part 1. New MRI Activitiy includes: Gd-enhancing MRI lesions on brain MRI scans; New T2 MRI lesions on brain MRI scans and newly enlarging MRI lesions on brain MRI scans

Time frame: At Weeks 24, 48 and 96

Time to First Relapse

Part 1

Time frame: Up to Week 96

Proportion of Participants Who Do Not Experience Relapse

Part 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Boston Children's Hospital

Boston, Massachusetts, United States

The Rector and Visitors of the University of Virginia

Charlottesville, Virginia, United States

Universitair Kinderziekenhuis Koningin Fabiola

Brussels, Belgium

Universitair Ziekenhuis Ghent

Ghent, Belgium

MHATNP 'Sv.Naum', EAD

Sofia, Bulgaria

University of Calgary - Alberta Children's Hospital

Calgary, Alberta, Canada

Fakultni nemocnice u sv. Anny v Brne

Brno, Czechia

Fakultni nemocnice Hradec Kralove

Hradec Králové, Czechia

Nemocnice Jihlava p.o.

Jihlava, Czechia

Fakultni nemocnice Ostrava

Ostrava, Czechia

...and 52 more locations

Time frame: Up to Week 96

Annualized Relapse Rate

Part 1

Time frame: At Weeks 48 and 96

Number of Participants That Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)

Part 1. Including prospective and follow-up of flushing, nausea, abdominal pain and diarrhea

Time frame: Up to Week 96

Fatigue as measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale Scores

Part 1. Multidimensional Fatigue Scale scores - designed as a generic symptom-speciﬁc instrument to measure fatigue in patients with acute and chronic health conditions as well as healthy school and community populations.

Time frame: Up to Week 96

Quality of Life as measured by the PedsQL

Part 1

Time frame: Up to Week 96

Change from Baseline to Week 96 in the Expanded Disability Status Scale (EDSS) Score

Part 1. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS.

Time frame: Up to Week 96

Vital Signs, Electrocardiograms (ECGs) and Changes in Clinical Laboratory Data, including Monitoring of Liver Function, Renal Function, Hematologic, and Coagulation Parameters

Part 1

Time frame: Up to Week 96

Annualized Relapse Rate

Part 2

Time frame: Up to 7 years

Change from Baseline in EDSS Score

Part 2. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS.

Time frame: Up to 7 years

Change from Baseline in Symbol Digit Modalities Test (SDMT) Score

Part 2. SDMT is used to assess processing speed. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. The score is number of correctly coded items from 0 (worst) to 110 (best). Higher scores indicate better performance.

Time frame: Up to 7 years

Change from Baseline in Brief Visuospatial Memory Test - Revised (BVMT-R) Score

Part 2. BVMT-R is used to assess learning/memory. The stimulus page is presented for 10 seconds, and the participant is then asked to reproduce the designs as accurately as possible and in the same location on the page. Three learning trials are administered, followed by a delay trial approximately 20 to 40 minutes later. Immediately following the delay trial a recognition trial is administered to see whether the participant recognizes the figures that were on the display.

Time frame: Up to 7 years

Change from Baseline in School Progression Query

Part 2. If permitted by the local regulatory authority, participants or caregivers will be posed the following question: "During the past year, did \[you/the subject\] progress from one \[class/grade-level\] to the next in school?"

Time frame: Up to 7 years

Number of Participants with Incidences of Clinically Relevant Vital Signs Abnormalities

Part 2

Time frame: Up to 7 years

Number of Participants with Incidences of Clinically Relevant ECG Abnormalities

Part 2

Time frame: Up to 7 years

Number of Participants with Incidences of Clinically Relevant Laboratory Assessment Abnormalities

Part 2

Time frame: Up to 7 years

Change from Baseline in Height

Part 2

Time frame: Up to 7 years

Change from Baseline in Weight

Part 2

Time frame: Up to 7 years

Change from Baseline in Bone Age

Part 2

Time frame: Up to 7 years

Tanner Stage

Part 2. Information regarding Tanner staging will be collected at baseline for all male participants and for female participants who are premenarche and will be stopped once the participant's bone age reaches ≥16 years or once the participant is postmenarche.

Time frame: Up to 7 years